#BEGIN_DRUGCARD DB03172

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
69-33-0

# ChEBI_ID:
48267

# Chemical_Formula:
C11H14N4O4

# Chemical_IUPAC_Name:
(2R,3R,4R,5S)-2-{4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-5-(hydroxymethyl)oxolane-3,4-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Antibiotics, Antineoplastic
Antimetabolites, Antineoplastic
Purine Nucleoside Phosphorylase inhibitor

# Drug_Interactions:
Not Available

# Drug_Reference:
721814	Zimmerman TP, Wolberg G, Duncan GS: Metabolism of tubercidin and formycin to their 3':5'-cyclic nucleotides in mammalian cells. J Biol Chem. 1978 Dec 25;253(24):8792-7.

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.80

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
3000 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Tubercidin

# HET_ID:
TBN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H14N4O4/c12-9-5-1-2-15(10(5)14-4-13-9)11-8(18)7(17)6(3-16)19-11/h1-2,4,6-8,11,16-18H,3H2,(H2,12,13,14)/t6-,7-,8+,11+/m0/s1

# InChI_Key:
InChIKey=HDZZVAMISRMYHH-LITAXDCLSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3172

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
266.2533

# Molecular_Weight_Mono:
266.101504956

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1PR5

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA152530738

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.83

# Predicted_LogS:
-1.2

# Predicted_Water_Solubility:
1.66e+01 g/l

# Primary_Accession_No:
DB03172

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936593

# PubChem_Substance_ID:
46505938

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03017

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC=NC2=C1C=CN2[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
7-Deazadenosine
7-deazaadenosine
Antibiotic 155B2T
Antibiotic XK 101-1
Sparsomycin A
TBN
Toyocamycin
Tubercidine

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:59 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M60917

# Drug_Target_1_GenBank_ID_Protein:
147309

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
deoD

# Drug_Target_1_Gene_Sequence:
>720 bp
ATGGCTACCCCACACATTAATGCAGAAATGGGCGATTTCGCTGACGTAGTTTTGATGCCA
GGCGACCCGCTGCGTGCGAAGTATATTGCTGAAACTTTCCTTGAAGATGCCCGTGAAGTG
AACAACGTTCGCGGTATGCTGGGCTTCACCGGTACTTACAAAGGCCGCAAAATTTCCGTA
ATGGGTCACGGTATGGGTATCCCGTCCTGCTCCATCTACACCAAAGAACTGATCACCGAT
TTCGGCGTGAAGAAAATTATCCGCGTGGGTTCCTGTGGCGCAGTTCTGCCGCACGTAAAA
CTGCGCGACGTCGTTATCGGTATGGGTGCCTGCACCGATTCCAAAGTTAACCGCATCCGT
TTTAAAGACCATGACTTTGCCGCTATCGCTGACTTCGACATGGTGCGTAACGCAGTAGAT
GCAGCTAAAGCACTGGGTATTGATGCTCGCGTGGGTAACCTGTTCTCCGCTGACCTGTTC
TACTCTCCGGACGGCGAAATGTTCGACGTGATGGAAAAATACGGCATTCTCGGCGTGGAA
ATGGAAGCGGCTGGTATCTACGGCGTCGCTGCAGAATTTGGCGCGAAAGCCCTGACCATC
TGCACCGTATCTGACCACATCCGCACTCACGAGCAGACCACTGCCGCTGAGCGTCAGACT
ACCTTCAACGACATGATCAAAATCGCACTGGAATCCGTTCTGCTGGGCGATAAAGAGTAA

# Drug_Target_1_General_Function:
Nucleotide transport and metabolism

# Drug_Target_1_General_References:
1714590	Hershfield MS, Chaffee S, Koro-Johnson L, Mary A, Smith AA, Short SA: Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7185-9.
3299264	Larsen JE, Albrechtsen B, Valentin-Hansen P: Analysis of the terminator region after the deoCABD operon of Escherichia coli K-12 using a new class of single copy number operon-fusion vectors. Nucleic Acids Res. 1987 Jul 10;15(13):5125-40.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
8506346	Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C: Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5011-5.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9351810	Mao C, Cook WJ, Zhou M, Koszalka GW, Krenitsky TA, Ealick SE: The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 1997 Oct 15;5(10):1373-83.
9653038	Koellner G, Luic M, Shugar D, Saenger W, Bzowska A: Crystal structure of the ternary complex of E. coli purine nucleoside phosphorylase with formycin B, a structural analogue of the substrate inosine, and phosphate (Sulphate) at 2.1 A resolution. J Mol Biol. 1998 Jul 3;280(1):153-66.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3683

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
25950

# Drug_Target_1_Name:
Purine nucleoside phosphorylase deoD-type

# Drug_Target_1_Number_of_Residues:
239

# Drug_Target_1_PDB_ID:
1PW7

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01048	PNP_UDP_1

# Drug_Target_1_Protein_Sequence:
>Purine nucleoside phosphorylase deoD-type
MATPHINAEMGDFADVVLMPGDPLRAKYIAETFLEDAREVNNVRGMLGFTGTYKGRKISV
MGHGMGIPSCSIYTKELITDFGVKKIIRVGSCGAVLPHVKLRDVVIGMGACTDSKVNRIR
FKDHDFAAIADFDMVRNAVDAAKALGIDARVGNLFSADLFYSPDGEMFDVMEKYGILGVE
MEAAGIYGVAAEFGAKALTICTVSDHIRTHEQTTAAERQTTFNDMIKIALESVLLGDKE

# Drug_Target_1_Reaction:
purine nucleoside + phosphate = purine + alpha-D-ribose 1-phosphate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cleavage of guanosine or inosine to respective bases and sugar-1-phosphate molecules

# Drug_Target_1_SwissProt_ID:
P0ABP8

# Drug_Target_1_SwissProt_Name:
DEOD_ECOLI

# Drug_Target_1_Synonyms:
EC 2.4.2.1
Inosine phosphorylase
PNP

# Drug_Target_1_Theoretical_pI:
5.35

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB03172
